Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Inclusion Criteria: * Male or female participants 6 months to less than 18 years of age at the time of informed consent/assent form was signed * Participants whose parent/LAR(s) have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them * Participants with macrocystic LM or mixed cystic LM (≥ 50% macrocystic disease measured by volume) of the Head/Neck/Mediastinum according to the ISSVA 2018 criteria (ISSVA 2018) measured via LM imaging at Screening to confirm, upon central review, the diagnosis of macrocystic or mixed cystic LM * Participants who may have had surgical or sclerotherapy treatment for their LM, but not within six months of the consent/assent form being signed Exclusion Criteria: * Penicillin allergy * Vascular tumors or combined vascular malformations * Microcystic LM or mixed cystic LM with predominant microcystic features * LMs of the orbit (orbital LM) as target cyst For more information on eligibility criteria, please contact the sponsor.